Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study - Takeaways - MDSpire

Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

  • By

  • Simran Chandra

  • Sagar Hansraj

  • Aakriti Adhikari

  • Ben Ponvilawan

  • Addison Tolentino

  • Dhruv Bansal

  • April 27, 2026

  • 0 min

Share

  • 1

    Dabrafenib and trametinib are effective for BRAF V600E-mutated lung adenocarcinoma but can cause HLH-like hyperinflammatory syndrome.

  • 2

    The patient required ruxolitinib for HLH-like syndrome management while continuing dabrafenib and trametinib, achieving disease control.

  • 3

    HLH is a serious immune-mediated toxicity associated with BRAF/MEK inhibitors, requiring prompt diagnosis and treatment.

  • 4

    Ruxolitinib, a JAK1/2 inhibitor, was effective in managing HLH-like symptoms without compromising cancer treatment.

  • 5

    This case highlights the importance of monitoring for HLH in patients receiving BRAF/MEK inhibitors and the potential for safe rechallenge.

Original Source(s)

Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

  • by Simran Chandra, Sagar Hansraj, Aakriti Adhikari, Ben Ponvilawan, Addison Tolentino, Dhruv Bansal

  • April 27, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases